Merck's earnings transcript highlights successful product launches like KEYTRUDA and ZEPATIER, along with strong non-GAAP EPS guidance exceeding previous expectations. Despite some currency headwinds, the management's optimistic outlook and strategic growth initiatives are likely to bolster investor confidence in the short term.

[1]